Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 12959-12970
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12959
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12959
Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
Shu-Peng Zou, Qian Cheng, Cheng-Yang Feng, Chan Xu, Ming-Hui Sun, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Author contributions: Zou SP and Cheng Q performed the research as well as screening, inclusion, and exclusion of randomized controlled trials, and wrote the paper; Sun MH designed the study; Feng CY and Xu C reviewed the data extracted from the study.
Conflict-of-interest statement: All the authors disclose no conflicts of interest for this paper.
PRISMA 2009 Checklist statement: The scheme of the study was successfully registered at PROSPERO (registration number: 42022326460).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Sun, PhD, Professor, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430000, Hubei Province, China. tjzoushupeng@163.com
Received: August 16, 2022
Peer-review started: August 16, 2022
First decision: September 26, 2022
Revised: October 8, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 16, 2022
Processing time: 120 Days and 3 Hours
Peer-review started: August 16, 2022
First decision: September 26, 2022
Revised: October 8, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 16, 2022
Processing time: 120 Days and 3 Hours
Core Tip
Core Tip: This is the first study to compare currently available first-line treatment regimens for eradication of antibiotic-resistant Helicobacter pylori strains. For clarithromycin-resistant and metronidazole-resistant strains, dual therapy containing a high-dose proton pump inhibitor (HDDT) shows an absolute advantage over other first-line therapies. There was a difference in the effectiveness of HDDT between all patients and patients with clarithromycin-resistant Helicobacter pylori infection. In the subgroup of high cure rates (≥ 90%), HDDT was also generally better than other therapies. The use of fewer antibiotics may be better to prevent global antibiotic resistance effectively.